ecnaЭкономика наукиEconomics of Science2410-132X2949-4680Delo Publishing house10.22394/2410-132X-2023-9-4-51-60ecna-432Research ArticleФИНАНСИРОВАНИЕ, ФОНДЫ И КАДРЫ НАУКИFUNDING AND STAFFING IN SCIENCEДолевое финансирование НИОКР на малых и средних инновационных предприятиях: пример китайской биомедицинской промышленностиShared funding of R&D in small and medium-sized innovative enterprises: the case of Chinese biomedical industryhttps://orcid.org/0000-0002-9661-0537СуньЯ.SunY.

Янхуэй Сунь – слушатель DBA, соискатель научной степени кандидата экономических наук, Главный исполнительный директор

Web of Science Researcher ID: JPX-9139–2023

Москва, пр. Вернадского, д. 82, стр. 1

Central Plaza, № 18 Harbour Road, район Ванчай, Гонконг

Yanhui Sun – DBA candidate and PhD candidate in Economic Science, Chief Executive Officer

Web of Science Researcher ID: JPX-9139–2023

Moscow, Prospect Vernadskogo, 82, build. 1

Central Plaza, No.18 Harbour Road, Wanchai District, Hong Kong

syhmba@foxmail.comИнститут экономики, математики и информационных технологий, Российская академия народного хозяйства и государственной службы при Президенте Российской Федерации (РАНХиГС); Pfiker BiopharmaКитайInstitute of Economics, Mathematics and Information Technology, Russian Presidential Academy of National Economy and Public Administration; Pfiker BiopharmaChina202321122023945160Copyright © Сунь Я., 20232023Сунь Я.Sun Y.This work is licensed under a Creative Commons Attribution 4.0 License.https://ecna.elpub.ru/jour/article/view/432

Данное исследование рассматривает вопросы корпоративного управления, стоящие перед малыми и средними инновационными биомедицинскими предприятиями в процессе выпуска акций. Статья ставит своей целью предложить рекомендации для успешного осуществления этого процесса. Для решения таких проблем, как неполная структуризация капитала, недостаточно эффективные финансовые системы контроля и невысокая устойчивость основного коллектива в процессе эмиссии, предлагаются меры для улучшения ситуации. В их числе: оптимизация внутренней системы управления, формирование эффективной структуры научно-исследовательских и опытно-конструкторских работ (НИОКР), внедрение практических механизмов стимулирования для прибыльно-ориентированных НИОКР и обеспечение присутствия технических экспертов в структуре управления компании. Выпуск акций играет значительную роль в решении вопросов, с которыми сталкиваются малые и средние инновационные биомедицинские компании, особенно в отношении развития инновационных фармацевтических продуктов и биомедицинских исследований. Таким образом, данная практика положительно влияет на активное развитие биомедицинского сектора Китая.

This study delves into the corporate governance challenges confronted by small and mediumsized innovative biomedical enterprises in the context of equity financing. Its objective is to provide valuable recommendations for the successful implementation of such financing. In order to address issues such as imperfect equity structure, inadequate financial audit systems, and low stability of the core team during equity financing, a range of improvement measures are proposed. These measures comprise optimizing internal management mechanisms, establishing an efficient R&D organizational structure, implementing practical incentive mechanisms for R&D enterprises focused on benefits, and enabling technical experts to actively engage in company ownership structures. Equity financing plays a vital role in resolving the difficulties faced by small and medium-sized innovative biomedical enterprises, particularly in fostering the development of innovative pharmaceutical products within the biomedical R&D field. Thus, it has a positive impact on effectively advancing China’s biomedical industry.”

малые и средние предприятияМСПбиомедицинская компаниявенчурный капиталакционерное финансированиекорпоративное управлениеНИОКРsmall and medium-sized enterprisesSMEbiomedical companyventure capitalVCequity financingcorporate governanceR&DReferencesCao, Y. (2005). Venture capital collaboration is an important financing method for pharmaceutical enterprises. China Pharmaceutical Industry, 14(11), 16–16. 曹阳 (2005) 风险投资协作是医药企业重要 的融资方式选择. 中国药业, 14(11), 16–16.Cao Y. Venture capital collaboration is an important financing method for pharmaceutical enterprises // China Pharmaceutical Industry. 2005. № 14(11). P. 16–16.Chen, K.A. (2004). Study on SME’s Financing Difficulties and Financial Support. Huazhong University of Science and Technology (Wuhan). 陈凯慧(2004) 中小企业融资困境及其金融支持研究. 华中科技大 学(武汉).Chen K. A. Study on SME’s Financing Difficulties and Financial Support. Huazhong University of Science and Technology (Wuhan), 2004Ding Jinxi, Ma Yilin. (2012). On the policy of innovative drug venture capital in the United States and its enlightenment to our country. Shanghai Pharmaceutical, 33(11), 41–44.丁锦希, 马依林 (2012) 论美国创 新药物风险投资政策及对我国的启示. 上海医药, 33(11), 41–44.Ding Jinxi, Ma Yilin. On the policy of innovative drug venture capital in the United States and its enlightenment to our country // Shanghai Pharmaceutical. 2012. № 33(11). P. 41–44.Gao Jian, Cheng Ming. (2002). On incentive and restraint mechanism and corporate governance structure. Journal of Shanxi University of Finance and Economics, 2, 39–39. 高键,程明(2002)论激励约束 机制与公司治理结构. 山西财经大学学报, 2, 39–39.Gao Jian, Cheng Ming. On incentive and restraint mechanism and corporate governance structure // Journal of Shanxi University of Finance and Economics. 2002. № 2. P. 39–39.Gao, B J. (2016). Research on innovative drug development strategy of pharmaceutical enterprises in our country. Medicine & Health: Abstract Edition, 11, 205–205. 高彬洁(2016) 我国制药企业创新药物研发战 略研究. 医药卫生:文摘版, 11,205–205.Gao B J. Research on innovative drug development strategy of pharmaceutical enterprises in our country // Medicine & Health: Abstract Edition. 2016. № 11. P. 205–205.Ge Dongsheng. (2012). Demand forecasting and inventory management of pharmaceutical enterprises – A case study of Tianjin SmithKline Corporation. Peking University.葛冬生 (2012) 医药企业的需求预测及 库存管理—以中美天津史克公司为例. 北京大学.Ge Dongsheng. Demand forecasting and inventory management of pharmaceutical enterprises – A case study of Tianjin SmithKline Corporation. Peking University, 2012.Guo Dandan, Feng Guozhong. (2015). Empirical analysis on influencing factors of R&D investment of large and medium-sized pharmaceutical manufacturing enterprises in China. China Pharmaceutical Affairs, 29(5), 466–470. 郭丹丹, 冯国忠 (2015) 我国大中型医药制造企业研发投入影响因素的实证分 析. 中国药事, 29(5), 466–470.Guo Dandan, Feng Guozhong. Empirical analysis on influencing factors of R&D investment of large and medium-sized pharmaceutical manufacturing enterprises in China // China Pharmaceutical Affairs. 2015. № 29(5). P. 466–470. 8. Huang J., Luo Y., Chen Z. Research on venture capital in biomedical high-tech field // Journal of Hunan Medical University (Social Science Edition). 2002. № 2. P. 29–32.Huang, J., Luo, Y., & Chen, Z. (2002). Research on venture capital in biomedical high-tech field. Journal of Hunan Medical University (Social Science Edition), 2, 29–32. 黄菊芳, 罗英姿, 陈主初(2002) 生物医 药高技术领域内的风险投资探讨. 湖南医科大学学报(社会科学版), 2, 29–32.Jin T. The role of Chinese enterprises in pharmaceutical technology R&D – and on the role of governmentJin, T. (2007). The role of Chinese enterprises in pharmaceutical technology R&D – and on the role of government funds and venture funds in it. Chinese Journal of Pharmaceutical Technology Economics and Management, 1(3), 49–51. 金拓(2007)中国企业在医药技术研发中的角色－兼论政府资金和风险资金 在其中的作用. 中国医药技术经济与管理, 1(3), 49–51.funds and venture funds in it // Chinese Journal of Pharmaceutical Technology Economics and Management. 2007. № 1(3). P. 49–51.Li, Sh. (2008). Prevention and Control of Private Equity Fund Management Risk. North China Electric Power University (Beijing). 李甚坊 (2008) 私募股权投资基金经营风险防范与控制. 华北电力大学(北京).Li Sh. Prevention and Control of Private Equity Fund Management Risk. North China Electric Power University (Beijing), 2008.Lin, J.W. (2018). Research on the impact of new medical reform policy on the development of pharmaceutical industry in our country. China Health Industry, 6, 181–182.林佳雯(2018) 新医改政策对 我国医药产业发展的影响研究. 中国卫生产业, 6, 181–182.Lin J. W. Research on the impact of new medical reform policy on the development of pharmaceutical industry in our country // China Health Industry. 2018. № 6. P. 181–182.Pu, L.C. (2008). Research on internal control problems of private SMEs. Economic Review, 5, 114–116. 蒲林昌(2008)民营中小企业内部控制问题研究. 经济纵横, 5, 114–116.Pu L. C. Research on internal control problems of private SMEs // Economic Review. 2008. № 5. P. 114–116.Qiang Fu. (2012). The application of effective motivation in enterprise human resource management. The Economist, 284(10), 225–226. 付嫱(2012) 有效激励在企业人力资源管理中的运用浅析. 经济师, 284(10), 225–226.Qiang Fu. The application of effective motivation in enterprise human resource management // The Economist. 2012. № 284(10). P. 225–226.Tang, X.J., Song, H.M. (2011). On our country listed company governance structure present situation and perfect countermeasure. Harbin University of Commerce Journal (Social Science Edition), 1, 31–34. 唐现杰, 宋惠民(2011) 论我国上市公司治理结构现状与完善对策. 哈尔滨商业大学学报(社会科学版), 1, 31–34.Tang X. J., Song H. M. On our country listed company governance structure present situation and perfect countermeasure // Harbin University of Commerce Journal (Social Science Edition). 2011. № 1. P. 31–34.Wu, L., Xu, L. (2020). The role of venture capital in SME loans in China. Research in International Business and Finance, 51(C). doi:10.1016/j.ribaf.2019.101081.吴隆, 徐磊(2020) 风险投资在中国中小企业贷款 中的作用. 国际商业和金融研究, 51(C). doi:10.1016/j.ribaf.2019.101081.Wu L., Xu L. The role of venture capital in SME loans in China // Research in International Business and Finance. 2020. № 51(C). doi:10.1016/j.ribaf.2019.101081.]Yang, M.Z., Ji, F.S. (2010). Private equity and its application in the financing of technology-based SMEs. Modern Management Science, 7, 34–36. 杨棉之,姬福松 (2010) 私募股权及其在科技型中小企业融资 中的应用. 现代管理科学, 7, 34–36.Yang M. Z., Ji F. S. Private equity and its application in the financing of technology-based SMEs // Modern Management Science. 2010. № 7. P. 34–36.Zhao Fang. (2001). Comprehensive analysis of venture capital. Guangdong Economy, 65(6), 34–37. 赵芳 (2001) 风险投资综论. 广东经济, 65(6), 34–37.Zhao Fang. Comprehensive analysis of venture capital // Guangdong Economy. 2001. № 65(6). P. 34–37.

The authors declare that there are no conflicts of interest present.